Welcome to our dedicated page for Bioceres Crop Solutions news (Ticker: BIOX), a resource for investors and traders seeking the latest updates and insights on Bioceres Crop Solutions stock.
Bioceres Crop Solutions Corp. (NASDAQ: BIOX) regularly issues news and updates that reflect its role in agricultural biotechnology, crop inputs and sustainable farming practices. Company announcements frequently describe new developments in its crop protection, seed and integrated products, and crop nutrition segments, as well as progress on its HB4 technology platform and biological solutions.
Investors and industry followers can use this news feed to monitor Bioceres’ financial performance, including quarterly and full-year results prepared under IFRS. Earnings releases typically cover revenues by segment, gross profit and margin trends, operating profit or loss, net income or loss and Adjusted EBITDA, along with commentary on working capital, cash flow and cost structure adjustments.
Bioceres’ news also highlights technology and regulatory milestones. Recent communications include the EPA registration of the Rinotec insecticide and nematicide platform in the United States, commercialization approvals in Brazil, and patent protection for HB4 wheat in the U.S. until 2042. The company has also reported a strategic collaboration with the Colorado Wheat Research Foundation to develop and commercialize HB4 wheat in the United States under an open licensing model.
Corporate governance and financing developments appear in the company’s updates as well, such as changes to the Board of Directors and senior management, amendments to note purchase agreements, and disclosures related to noteholder communications and litigation. By following this page, readers can track how Bioceres communicates its segment performance, capital structure actions and progress on its biotech and biological platforms across key agricultural markets.
Bioceres Crop Solutions (NASDAQ: BIOX) reported fiscal 1Q26 results for the quarter ended September 30, 2025. Total revenues were $77.5 million, down 17% YoY as the company reduced low-margin, working-capital-intensive sales and completed a seed-model transition. Gross profit was $36.2 million and gross margin expanded to 46.7% from 40.2% (651 bps). Adjusted EBITDA rose to $13.6 million (+61% YoY) while GAAP net loss was $7.5 million versus a $6.2 million loss a year earlier. Management highlighted margin improvement and cost discipline.
Bioceres Crop Solutions (NASDAQ: BIOX) will host its fiscal first quarter 2026 earnings conference call on Thursday, November 13, 2025 at 8:30 a.m. ET to discuss results for the quarter ended September 30, 2025. A press release with results will be issued prior to the call.
Bioceres Chairman & CEO Federico Trucco and Head of Investor Relations Paula Savanti will host the call, which includes a presentation available via webcast and an investor relations page. Replay will be available through November 20, 2025.
Bioceres Crop Solutions (NASDAQ: BIOX) has formed a strategic partnership with the Colorado Wheat Research Foundation (CWRF) to develop and commercialize HB4® wheat in the United States. Through this collaboration, CWRF will receive exclusive, sublicensable rights to the HB4® trait in the U.S. and serve as Trait Manager.
The partnership aims to create a next-generation wheat production system combining climate resilience with sustainable weed management. The companies will jointly develop new broad-spectrum herbicide formulations specifically for HB4® wheat, integrated with Bioceres' biological solutions. Bioceres will maintain leadership of regulatory activities while ensuring alignment with U.S. Wheat Industry Principles for Biotechnology Commercialization.
The HB4® trait will be available through an open licensing model to all interested public and private wheat breeding programs in the U.S.Bioceres Crop Solutions (NASDAQ: BIOX) reported challenging financial results for Q4 and FY2025. Total revenues declined to $74.7 million in Q4 (-40% YoY) and $335.3 million for FY25 (-28% YoY), primarily due to weaker demand in Argentina and lower HB4-related sales.
The company reported a Q4 net loss of $48.0 million and FY25 net loss of $55.2 million. Despite profitability challenges, net cash flow from operations improved by 27% YoY to $53.0 million in FY25. The company maintained a relatively stable full-year gross margin at 39%, supported by higher-value proprietary products.
In response, management is implementing cost-cutting measures, targeting 10-12% operating expense savings and reducing CAPEX and R&D investment rates by 50% to 2.5-3% of sales for FY26 and FY27.
Bioceres Crop Solutions (NASDAQ: BIOX), a company focused on agricultural ecosystem regeneration and climate-resilient crop solutions, has scheduled its fiscal fourth quarter and full year 2025 financial results conference call for Tuesday, September 9, 2025, at 8:30 a.m. ET.
The conference call will be hosted by CEO Federico Trucco and Head of IR Paula Savanti, featuring a presentation and Q&A session. Financial results will be released before the call, with presentation materials available through the company's investor relations website. A replay will be accessible until September 16, 2025.
Bioceres Crop Solutions (NASDAQ: BIOX), a company specializing in agricultural productivity solutions and ecosystem regeneration, has scheduled its fiscal third quarter 2025 financial results conference call for Wednesday, May 21, 2025, at 8:30 a.m. ET. The company will release its financial results for the quarter ended March 31, 2025, before the call.
The conference call will feature key executives including CEO Federico Trucco, CFO Enrique Lopez Lecube, CCO Milen Marinov, and Head of IR Paula Savanti. A presentation will accompany the webcast, accessible through the company's investor relations website. The call replay will be available until June 4, 2025.
Bioceres Crop Solutions (NASDAQ: BIOX) has received EPA federal registration for Rinotec, its innovative insecticide and nematicide platform. The product, which is exempt from residue tolerance requirements due to its negligible risk to human health and non-target organisms, has already secured approval for commercialization in Brazil.
The Rinotec platform features a unique metabolite-based approach to biologicals that enables significant dose reductions while maintaining the efficiency of synthetic chemical pesticides. This makes it suitable for both row and specialty crops. With registrations in both the U.S. and Brazilian markets, BIOX is now positioned to advance its regulatory and commercial strategies in two of the world's largest agricultural economies.
Bioceres Crop Solutions (NASDAQ: BIOX) has received a Notice of Allowance from the USPTO for its first event-specific patent covering HB4 Wheat, securing protection until 2042. This is the first of four potential patents for HB4 Wheat in the United States.
HB4 wheat technology offers improved drought tolerance and enhanced weed management compared to conventional wheat. The technology has already received USDA approval for cultivation and FDA approval for food and feed use in the U.S., which is the fourth largest wheat producer with nearly 40 million acres harvested in the most recent marketing year.
The company will follow the U.S. Wheat Associates' biotechnology commercialization principles, including securing regulatory approvals in major export markets, establishing tolerance thresholds, providing trait detection tests, and implementing product stewardship. The commercial rollout will utilize a broad licensing approach.
FAQ
What is the current stock price of Bioceres Crop Solutions (BIOX)?
What is the market cap of Bioceres Crop Solutions (BIOX)?
